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The ROCO proteins are a family of large, multidomain proteins characterised by the presence of a Ras of
complex proteins (ROC) domain followed by a COR, or C-terminal of ROC, domain. It has previously been
shown that the ROC domain of the human ROCO protein Leucine Rich Repeat Kinase 2 (LRRK2) controls
its kinase activity. Here, the ability of the ROC domain of another human ROCO protein, Death Associated
Protein Kinase 1 (DAPK1), to bind GTP and control its kinase activity has been evaluated. In contrast to
LRRK2, loss of GTP binding by DAPK1 does not result in loss of kinase activity, instead acting to modulate
this activity. These data highlight the ROC domain of DAPK1 as a target for modifiers of this proteins
function, and casts light on the role of ROC domains as intramolecular regulators in complex proteins with
implications for a broad range of human diseases.
T
he human ROCO proteins are defined by the presence of a GTPase domain, termed ROC for RAS of complex
proteins, followed by a COR (c-terminal of ROC) domain1. The family consists of four members: Leucine Rich
Repeat Kinases 1 and 2 (LRRK1 and LRRK2), Death Associated Protein Kinase 1 (DAPK1) and MFH-
amplified sequences with Leucine Rich tandem repeats 1 orMASL12. All four have links to human disease: mutations
in LRRK2 are the most common genetic cause of Parkinson’s disease (PD)3, and all of the human ROCO proteins
have been linked to cancer2. More recently, genome wide association studies have identified the LRRK2 locus as being
involved in susceptibility to sporadic PD, Crohn’s disease and leprosy4-6. With regard to DAPK1 in particular,
alterations in the expression and activity of this protein are associated with changes in cell proliferation and control of
cell death7,8, and both silencing and mutations of DAPK1 altering its expression have been linked to chronic
lymphocytic Leukaemia9. Because of this, DAPK1 has been highlighted as a potential therapeutic target in cancer10,11.
In addition to its links with cancer, several studies have suggested that DAPK1may play a role in Alzheimer’s disease,
although these data remains controversial12,13. A genetic link between DAPK1 and PD has been examined, with no
evidence that genetic variability in the DAPK1 gene alters the risk of developing the disease14.
To understand how this family of complex, multidomain proteins operates in a cellular context, and how their
dysfunction leads to disease, it is important to gain an insight into how their individual domains relate to one
another. Structural studies would be themost informative approach, describing the precise spatial arrangement of
domains, however to date only fragments of the ROCO proteins have been purified to the point where crystal-
lographic studies have been feasible and have provided only partial information as to domain/domain interac-
tions15-18. Three of the ROCOproteins contain kinase effector domains (LRRK1, LRRK2 andDAPK1). In all three
cases, targeted mutagenesis of individual domain activities has proved revealing as to how the various domains
relate to each other – in the case of LRRK1 and LRRK2, disruption of the GTP binding properties of the ROC
domain have been reported to have a dramatic impact on the kinase activities of these proteins19,20. This has led to
the suggestion that the ROC and kinase domains in these proteins act in amanner analogous to the small GTPases
and kinase such as Ras and Raf, with the ROC domain acting to regulate the kinase activity21. Ablation of the
kinase activity of DAPK1 results in a decrease in the action of the Death domain of this protein22. Similar to this,
artificial lowering of LRRK2’s kinase activity either bymutations or inhibitors has been shown to decrease toxicity
associated with PD linkedmutations23-25. Because of the data linking the kinase activities of LRRK2 andDAPK1 to
cell death, the kinase domains of these proteins have been identified as potential therapeutic targets in cancer and
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PD respectively26,27. Bioinformatic analysis of the amino acid
sequences of the kinase domains of the human LRRK genes and
DAPK1 has revealed that they belong to different kinase families28.
Furthermore, the kinase domain of DAPK1 is N-terminal of the
ROC-COR module whereas in LRRK1 and 2 the kinase domains
are at the C-terminus suggesting distinct structural interactions.
Coupled to data revealing that the ROC and COR domains of these
three proteins are closely related, this has led to the suggestion
that the kinase domains of the LRRK proteins transferred to the
ROCO family in a separate evolutionary event to the transfer of
kinase domain of DAPK129. This, in turn, raises the possibility that
the intramolecular regulation of kinase activity is different inDAPK1
compared to the LRRK proteins. A recent study by Carlessi et alia
examined these issues, demonstrating that the ROC domain of
DAPK1 is indeed a GTP binding domain and that loss of GTP
binding acts to increase, rather than decrease, the kinase activity of
DAPK1 due to loss of an inhibitory phosphorylation event30. The
data presented in this study replicate that reported by Carlessi et alia,
further supporting the thesis that the ROC domain of DAPK1 can
bind GTP, and examines how the loss of GTP binding impacts on the
kinase activity and the ability of this protein to form a complex under
native conditions.
Results
To examine the role of the ROC domain in the function of DAPK1,
an artificial mutation - T701N - was generated in the ROC domain of
DAPK1, designed to exclude GTP from its binding pocket based
upon sequence homology to equivalent residues in LRRK2 which
have been demonstrated to prevent GTP binding19,31-34 (Figure 1A-
C). This mutant was used to investigate the GTP binding properties
of DAPK1 in comparison with the wild type protein. HA tagged wild
type DAPK1 is capable of binding to GTP immobilized on sepharose
beads, an interaction that can be interrupted by the addition of a
molar excess of GTP (figure 2A). As predicted, the T701N mutation
is unable to bind the GTP resin thus acting to disrupt the binding
of DAPK1 to GTP (figure 2A). To examine whether endogenous
DAPK1 displays the same properties as epitope tagged DAPK1,
HEK293T cell lysates were examined in the same way and, using
an antibody specific for DAPK1, both binding to GTP sepharose
and disruption of this interaction upon addition of a molar excess
of GTP were apparent (figure 2B), with enrichment of DAPK1 in the
precipitated fractions. This data verifies the GTP binding properties
of DAPK1 at the endogenous level.
Having established that DAPK1 is a GTP binding protein, the
impact of GTP binding upon the kinase domain was investigated.
To assess this, the kinase activity of immunoprecipitatedDAPK1was
measured in an in vitro kinase assay as previously described25
(figure 3A). A K42W mutation, which is predicted to interfere with
the ability of DAPK1 to bind ATP35, was used as control to exclude
the possibility that any 32P incorporation observed was not due to
Figure 1 | (A) Sequence alignment of DAPK1 and LRRK2 (left panel) and
DAPK1 and the prokaryotic ROCO protein from Chlorobium tepidum
(right panel) showing shared residues. (B) Crystal structure of the
Chlorobium tepidum ROCO protein ROC-COR fragment (co-ordinates
taken from reference 16, PDB reference 3PDU) showing dimeric complex
(monomer one coloured blue, monomer two coloured turquoise). The
GxxxxGKT motif in the GTP binding pocket is highlighted in red for
monomer one. (C) Magnified view of the GTP binding pocket of the
Chlorobium tepidum ROCO protein showing the T644 residue, equivalent
to the T701 residue in DAPK1.
Figure 2 | (A)GTPbinding bywild type andGTP binding deadmutatedHA-taggedDAPK1, showing input lysates (lower panel) andDAPK1precipitated
by binding to GTP-agarose beads. The T701Nmutated form of DAPK1 was unable to bind GTP-agarose. The interaction of wild type DAPK1 with GTP
could be disrupted by the addition of a molar excess of GTP. (B) Interaction of endogenous DAPK1 expressed in HEK293 cells with GTP.
www.nature.com/scientificreports
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heterologous kinases co-precipitating with DAPK1. There was no
observable impact of GTP binding properties of DAPK1 (as modu-
lated by the T701N artificial mutation) upon its kinase activity,
compared to wild type protein as measured by autophosphorylation
(quantified data normalized to immunoprecipitated protein shown
in figure 3B). In contrast, the T701N mutation resulted in a signifi-
cant increase in activity compared to wild type protein as measured
by the phosphorylation of the generic kinase substrate Myelin Basic
Protein (figure 3C). Relative autophosphorylation was alsomeasured
in the absence of a generic substrate, again with no significant dif-
ference between wild type and T701N kinase activity (data not
shown).
To investigate whether the T701N mutation has an impact on the
cellular localisation of DAPK1, HEK293T cells transfected with wild
type and T701N DAPK1 were examined by immunocytochemical
labelling (figure 4). Wild type, K42W and T701N DAPK1 displayed
similar patterns of staining.
DAPK1 and LRRK2 have been demonstrated to form complexes
consistent with functioning as a dimer, and so to examine the impact
of alterations in enzymatic activity upon the ability of DAPK1 to
form a dimer, size exclusion chromatography (SEC) was undertaken
with cell lysates from cells transfected with the HA tagged wild type,
kinase dead and GTP binding dead forms of the protein respectively
(figure 5A quantified average data, 5B representative dot blot, and 5C
representative western blot). In contrast to LRRK2, loss of GTP
binding or kinase activity of DAPK1 does not result in disruption
of an individual chromatographic peak. However, while the wild type
and the K42W forms eluted at< 400 kDa consistent with a dimeric
complex, the T701Nmutation caused the protein to fractionate along
a broader range of molecular weights. To use an alternative approach
to examine complex formation by DAPK1, blue native gel electro-
phoresis was undertaken with cell lysates expressing the wild type,
T701N and K42W mutants (Figure 5D). Bands consist with the
observed peaks from SEC analysis were present at < 400 kDa for
wild type, K42W and T701N. However, the T701N mutant also
exhibits an unresolved smear above the 400 kDa band, consistent
with the SEC results.
Finally, immunogold electron microscopy (EM) was used to ex-
amine the oligomeric state of DAPK1 (figure 6). Lysates from
HEK293T cells transiently transfected with HA-DAPK1 wild type
were subjected to SEC and the fraction corresponding to the 400 kDa
peak diluted 20 times and analysed by immunogold EM. As shown in
figure 6A, gold-labelled particles display a pattern of doublets that are
consistent with a dimeric DAPK1 complex. Gold particles were occa-
sionally observed organized in triplets or even higher order com-
plexes, suggesting that oligomers larger than dimers may co-exist.
To rule out that these apparent DAPK1 dimers are not due to a sto-
chastic event, the frequency distribution of particle distances was
calculated and normalized by the annulus area within which the
particles were counted, since the probability of finding a particle
within a given annulus increases in proportion to the area of that
annulus. The distribution frequency plot of particle distances mea-
sured from different EM fields (n 5 559) indicates a clear peak
around 20 nm supporting the thesis that DAPK1 is able to form
dimers and, possibly, higher order oligomers (figure 6B). The
T701N mutant was also investigated using immunogold labelling.
Similar to the wild-type, gold labelled doublets were observed in the
400 kDa fraction of DAPK1-T701N (quantified data shown in
figure 6C) but a significantly smaller number of total gold particles
were found compared to the wild-type protein (an average of 29 gold
Figure 3 | (A) Representative autoradiograph and immunoblot analysis of the kinase activity of wild type and T701N forms of DAPK1. The upper panel
shows autophosphorylation activity as represented by incorporation of 32P. The middle panel shows immunoreactivity for HA tagged DAPK1
immunoprecipitated for the assay. The lower panel shows phosphorylation of Myelin basic protein by DAPK1. B) Quantified phosphorylation is
displayed corrected for total protein as quantified by immunoblot (mean and standard error displayed). Autophosphorylation levels were equivalent in
the wild type and T701N assays, and both were significantly different (n53, 1 way ANOVA with Tukeys post hoc correction) to the K42W assay. (C)
Phosphorylation of MBP (quantified phosphorylation, arbitrary units). T701N displayed significantly higher phosphorylation than wild type protein
(n53, 1 way ANOVA with Tukeys post hoc correction).
www.nature.com/scientificreports
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particles per micrograph for the wild-type compared to 11 gold
particles per micrograph for the T701N mutant). This is consistent
with the observation that this mutant also fractionates at higher
molecular weights and is therefore spread among a larger number
of fractions compared to the wild-type under conditions of equal
total protein (as shown in figure 5C).
Discussion
The data from this study demonstrates that DAPK1 is a GTP binding
protein, that the GTP binding properties of its ROC domain act to
modulate the kinase activity of this protein and that DAPK1 forms a
complex consistent with a dimeric active conformation. This data
replicates and extends the recent study by Carlessi and co-workers
examining the role of the ROC domain of DAPK1 in regulating
protein function30.
To investigate whether DAPK1 has a functional ROC domain two
approaches were used: competitive binding using GTP sepharose
and GTP free in solution, and a genetic approach using a targeted
point mutation in the predicted GTP binding pocket of the DAPK1
ROC domain. GTP binding was demonstrated using HA tagged and
endogenous DAPK1, with the T701Nmutation prevented binding of
HA tagged DAPK1 to GTP sepharose beads. It is possible that the
introduction of the T701Nmutation into the GTP binding pocket of
DAPK1, and the subsequent exclusion of GTP, results in a destabi-
lisation of the tertiary and quaternary structure of the protein.
Although it was not possible to directly examine whether DAPK1
containing the T701N mutation is correctly folded, several indirect
strands of evidence suggest that the T701N mutation does not result
in the misfolding and aggregation of DAPK1. First, steady state ex-
pression of DAPK1 is not altered by the introduction of the T701N
mutation. If the T701N mutation destabilised DAPK1, it would be
expected that steady state expression would be lower as the protein is
targeted for disposal. Secondly, both wild type and T701N DAPK1
display similar cytoplasmic expression patterns – if the T701Nmuta-
tion destabilised DAPK1 as a whole a possible outcome of this would
be its localisation to inclusion bodies as the cell attempts to remove
the misfolded protein. Finally, the T701N form of DAPK1 has a
catalytically active kinase domain, demonstrating that the kinase
domain is correctly folded. Whilst this does not provide evidence
regarding the folded state of the other domains in DAPK1, it suggests
that the T701Nmutation does not result in a complete destabilisation
of the holoprotein.
With regard to the impact of the T701Nmutation on kinase activ-
ity, it is notable that, in contrast to LRRK2, the loss of GTP binding
for DAPK1 does not result in an overall decrease in autophosphor-
ylation. Intriguingly, the T701N mutation increases the activity of
DAPK1 towards a generic substrate, MBP. This is consistent with the
increase in DAPK1 kinase activity towards Myosin Light Chain
described by Carlessi and co-workers. This suggests that the action
of the ROC domain as an intramolecular regulator is more complex
than a simple on/off switch as initial data from the leucine rich repeat
kinases suggested, whilst highlighting the importance of this domain
in the regulation of kinase activity21 and its potential as a drug target.
Recent data investigating the biology of the ROC domain in regulat-
ing LRRK2 has highlighted the complex nature of the regulatory role
of this domain34,36, with a study investigating the role of the WD40
domain of LRRK2 on the kinase activity of the protein further
emphasising the multiple levels of regulation that govern ROCO
protein biology37.
There are a number of strands of evidence that suggest that the
ROCO proteins are functionally active as dimeric complexes15,38-42,
although this has been re-examined in a recent paper43. A previous
study examined the ability of the human ROCO proteins to homo-
and heterodimerise, and reported that DAPK1 was able to form a
homodimer and had the capacity to form heterodimers with LRRK1
and LRRK244. It has also been reported that loss of GTP binding, and
ablation of kinase activity, in LRRK2 can act to disrupt dimer forma-
tion38. The data in this study examining the impact of loss of GTP
binding or kinase activity on the ability of DAPK1 to form a dimer
contrasts markedly with data for LRRK2.Whereas loss of GTP bind-
ing/kinase activity results in the disruption of putative dimer forma-
tion in LRRK2, this is not the case for DAPK1. Loss of kinase activity
has no significant impact on the apparent size of the complex formed
by DAPK1, while the T701N mutation results in a protein that frac-
tionates along a broader range of molecular weights. There are sev-
eral possible reasons for this change in complex size as measured by
Figure 4 | Immunocytochemical analysis of DAPK1 wild type (A) K42W
(B) andT701N (C) expression inHEK293T cells. No significant alteration
in cellular localisation was observed due to the insertion of the artificial
mutations. Scale bar represents 20 mm in main image, 10 mm in magnified
view.
www.nature.com/scientificreports
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SEC. First, it is possible that DAPK1 is in equilibrium among different
oligomeric states (dimers, trimers, tetramers and/or higher order
oligomers) with GTP binding favouring the dimeric conformation.
This scenario is supported by the immunogold EM results, which
highlight the presence of higher order oligomers other than the dimer
(figure 6A). Loss of GTP binding alters the oligomeric state of
DAPK1 shifting the equilibrium toward other conformers (trimers,
tetramers or higher order oligomers). Second, the GTP binding could
act to regulate the recruitment of a co-factor protein(s). As a con-
sequence, loss of GTP binding would lock the protein into a bound
state and therefore cause the apparent complex mass to increase.
Finally, GTP could function as an allosteric regulator, with loss of
GTP binding influencing the three dimensional conformation of the
enzyme. Allosteric transitions are common among enzymes and are
often associated with a shift between two structurally different states
(for example, from a compact to a more elongated conformation)45,46.
Therefore Apo-DAPK1 may possess a more open conformation,
thereby increasing the hydrodynamic radius and the apparent relative
molecular mass of the complex observed in the chromatogram.
Although this hypothesis would be consistent with a model for
ROCO function proposed by Gasper and co-workers40 it seems the
less likely given that the T701N protein displays increased polydisper-
sity rather than a clear shift in molecular weight. Determining which
of these possibilities is correct will require further investigations.
Figure 5 | (A) Size exclusion chromatography analysis of DAPK1wild type,
K42W and T701N. Data represents average of 3 independent experiments,
with independent replicates shown by individual dots. (B) Representative
dot blots for wild type, K42W and T701N DAPK1. (C) Representative
western blots of peak fractions for wild type, K42W and T701N DAPK1.
(D) Blue native gel electrophoresis analysis of wild type, K42W and T701N
DAPK1.
Figure 6 | Transmission electron microscopy analysis of DAPK1
overexpressing cell lysates. (A) Representative EM image of immunogold
labeled samples from chromatographic fractions corresponding to the 400
kDa peak. Bar is 50 nm. (B) Analysis of frequency distributions of distances
among gold particles for wild type DAPK1 normalized by the annulus area,
with the annulus thickness corresponding to the bin size (5 nm) (C) Analysis
of frequency distribution for T701N DAPK1 normalized by the annulus
area, with the annulus thickness corresponding to the bin size (5 nm).
www.nature.com/scientificreports
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To complement the SEC data, immunogold EMwas performed to
examine directly the quaternary structure of DAPK1 from the SEC
peak. These data provide the first direct evidence that DAPK1 can
form dimers and suggest that dimerizationmay be a common feature
among ROCO proteins42. One possibility is that DAPK1, and ROCO
proteins in general, function as G proteins activated by nucleotide
dependent dimerization to modulate kinase activity40. If dimeriza-
tion is a required step for GTP binding/hydrolysis but not for kinase
activity, then the observation that the GTP dead mutant T701N, but
not the K42W kinase deadmutant, displays a different SEC profile to
the wild type protein supports this notion. The TEM data in this
study, however, do not suggest a major disruption of quaternary
structure, highlighting that this aspect of DAPK1 biology requires
further investigation and that atomic resolution structural data cov-
ering multiple domains of DAPK1 is an important unmet need.
The data from this study replicates data previously reported by
Carlessi and co-workers. Despite different experimental conditions
(for example: different epitope tags – the current study used HA
tagged DAPK1 whereas the majority of experiments in the Carlessi
study used a flag tag – and different generic kinase substrates – mye-
lin basic protein in this study, maltose binding protein in Carlessi
et alia), the results described above are broadly consistent with the
previous study. In particular, the analysis of kinase activity and of
complex formation for wild type and T701N DAPK1 reveal similar
outcomes, suggesting that these are robust effects. Using blue native
PAGE and TEM, this current study has extended the findings of
Carlessi et alia regarding complex formation, supporting the conclu-
sions reached using SEC.
In summary, this study confirms that DAPK1 is indeed a GTP
binding protein and that loss of GTP binding results in an increase in
phosphorylation activity directed towards a generic substrate com-
pared to wild type protein, with no apparent increase in autopho-
sphorylation demonstrating that there is an intramolecular regu-
lation of function in DAPK1. SEC and TEM analysis of DAPK1
confirms that it exists under native conditions in a complex consist-
ent with a dimeric structure, and that loss of kinase activity does not
alter this complex. Loss of GTP binding results in an increase of
DAPK1 polydispersity, indicating that GTP binding may stabilize
one conformation, i.e. the dimer. These data present a stark contrast
with the impact of GTP binding in LRRK1 and LRRK2, two further
members of the human ROCO protein family, and highlight the
complex regulation of the function of this family.
Methods
Constructs. N-terminal HA tagged DAPK1 constructs were obtained from
Genecopoeia (www.genecopoeia.com). Site directed mutagenesis was carried out
using the Quikchange II mutagenesis kit (Agilent) as described in the manufacturers
instructions. Primer sequences are available from the authors upon request. All
constructs were verified by sequencing prior to use.
Cell culture.HEK293T, and COS7 cells were obtained from ATCCH (line identifiers
CRL-1573 and CRL-1651 respectively) and cultured in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum (Invitrogen) at 37uC in 5% CO2 prior to use.
Sequence alignment and structural modelling. Protein sequences were downloaded
from RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq/). Sequence alignments were
carried out using protein BLAST (http://blast.ncbi.nlm.nih.gov/). Co-ordinates for
the crystal structure of the Chlorobium tepidum ROCO protein (taken from reference
16, accession number 3PDU) were downloaded from the Protein Database (http://
www.rcsb.org/pdb/home/home.do). Images were generated using Chimera (http://
www.cgl.ucsf.edu/chimera/).
DAPK1 expression and GTP pulldown assays. HA-DAPK1 was transfected into
COS7 cells using fugene 6HD (Roche) as described in themanufacturers instructions.
24 hours after transfection, cells were harvested in lysis buffer G (100 mM Tris–HCl
pH 7.5, 50 mM KCl, 5 mMMgCl2 1 mM EDTA, 0.1 mMDTT, 1% Triton X-100 and
1x complete protease inhibitor cocktail, Roche), lysed for 30 minutes at 4uC with
rotation and precleared with 35 ml of 50% sepharose beads. Lysates were clarified by
centrifugation at 10000 g at 4uC for 10 minutes and the supernatants used in
subsequent experiments. DAPK1 expression was verified by immunoblotting
following BCA assay (Pierce, as per manufacturers instructions), with 10 mg of lysate
loaded onto 4-12% Bis Tris gels (Invitrogen) following denaturation in 4x sample
buffer (Invitrogen) supplemented with 5% b-Mercaptoethanol (Sigma). Proteins
were transferred to PVDF membrane (Millipore) and membranes blocked with 5%
milk solution in Phosphate buffered saline for 1 hour prior to probing with primary
(90 minutes) and secondary (60 minutes) antibodies. Membranes were washed three
times in PBS supplemented with 1% tween, and incubated with Pierce Supersignal
ECL substrate. Membranes were exposed to Kodak biomax film and developed on a
Kodak developer as per manufacturers instructions.
Kinase assays. kinase assays were carried out as previously described31. Briefly,
DAPK1 constructs were transfected as above. Cells were isolated in cell signalling
lysis buffer (Cell Signaling) plus protease inhibitors (Roche) and subjected to lysis
in the presence of 35 ml of sepharose beads for 30 minutes with rotation at 4uC.
Following clarification of lysates by centrifugation at 5000 g at 4uC for 10 minutes,
the supernatants were immunoprecipited with 35 ml of anti HA-agarose beads
(Sigma). These were washed five times with 500 ml of PBS supplemented with 1%
triton-X 100, followed by a final wash with 500 ml of kinase buffer (Cell Signaling)
and re-suspension in 30 ml of kinase buffer. To this was added 1 ml of ATP labelled
with 32P at the c phosphate position to a final concentration of 50 nM (specific
activity 3000 Ci/mmol) (Perkin Elmer). Assays were incubated for 1 hour at 30uC
with shaking. The assay was terminated by denaturation in 4x sample buffer
(Invitrogen) plus 5% b-Mercaptoethanol (Sigma) and run on 4-12% Bis Tris gels
(Invitrogen). Following transfer onto PVDF membrane, the membranes were
exposed to a phosphorscreen for 48 hours and scanned using a STORM 840
phosphorimager (GE Healthcare). Membranes were subsequently probed for total
protein as described above. Band intensities were quantified using ImageJ (NIH)
and the kinase activity for each construct corrected for total protein.
Immunocytochemistry (ICC). For immunocytochemistry HEK293T cells were
grown on 5 mg/ml poly-D-lysine (Sigma) coated coverslips and fixed with 4% PFA at
room temperature for 10 minutes. Fixed cells were blocked with 15% normal goat
serum (NGS) in PBS-T (PBS containing 0.1% Triton-X) prior to incubation with
primary antibodies in 10% NGS PBS-T (1:2000 rat anti-HA, Roche; 1:1000 mouse
anti-LAMP1, Abcam). Next cells were incubated with fluorescently labeled secondary
antibodies in 10% NGS in PBS-T (goat anti rat 488, goat anti mouse IgG1 568
respectively) before being counterstained with DAPI at 1:2000 in PBS and mounted
onto glass slides (VWR) using Fluoromount G mounting medium
(SouthernBiotech). F-Actin was detected by staining with 1:300 Alex fluor 633
phalloidin (Life Technologies). Finally images were obtained using a LSM 710
confocal microscope and images were compiled using Adobe Photoshop.
Blue Native Gel Electrophoresis. Blue native gel electrophoresis was carried out
using the Native PAGE system (Life technologies) as per manufacturers instructions.
Confluent 10 cm diameter plates of HEK293T cells transfected with wild type, K42W
andT701NDAPK1 constructs were harvested and lysed in 5%digitonin. 20 ml of each
lysate was loaded onto 3-12%BlueNativePAGE gels and run at 150V for 110minutes.
Gels were transferred to PVDF membrane as described above with the addition of
0.1% SDS to the transfer buffer.
Size Exclusion Chromatography (SEC). Transiently transfected HEK293T were
harvested in LB and cleared lysates (0.5ml) were injected and separated on a Superose
6 10/300 column (GE Healthcare). The column was per-equilibrated with buffer
(20mMTris-HCl pH 7.5, 150mMNaCl and 0.07%Tween 20) and used at a flow rate
of 0.5 ml/min. Elution volumes of standards were 7.5 ml for Blue Dexatran (V0), 11.5
ml for hemocianin from Carcinus aestuarii (900 kDa), 12 ml for thyreoglobin
(669 kDa), 14 ml for ferritin (440 kDa), 15.5 ml for catalase (232 kDa) and 17 ml for
aldolase (158 kDa). Elution fractions were analyzed by dot blot (see below).
Dot Blot.One microliter of each fraction from SEC was applied onto a nitrocellulose
membrane. The membrane was blocked with 5% milk for 1 hour and subsequently
incubated with rat monoclonal anti-HA clone 3F10 (Roche) followed by secondary
anti-rat IgG (Sigma) in 5% (w/v) milk.
Transmission electron microscopy. HA-DAPK1 positive fractions collected after
SEC were combined and diluted 20 times. Aliquots of HA-DAPK1 enriched
samples were adsorbed to a glow-discharged carbon-coated copper grid and
subsequently gold-labelled with mouse monoclonal anti-HA for one hour. After
washing, samples were incubated with 5 nm gold-labelled mouse anti IgG
secondary antibody for one hour. Negatively stained samples were prepared using
previously described methods47. Each gold labelled grid was washed with two
drops of deionized water, and stained with two drops of freshly prepared 1%
uranyl acetate. Samples were imaged at room temperature using a Fei Tecnai T12
electron microscope equipped with a LaB6 filament and operated at an
acceleration voltage of 100 kV. Images were taken at calibrated magnifications in
the range 11,000 x to 26,000 x.
The distribution of distances among all immunogold labelled proteins (n5559)
was obtained using ImageJ (NIH, Bethesda, MD, USA). Distances greater than 100
nm were discarded from the analysis. Frequency distribution of particles distances
was carried out using graph Prism setting 5 nm as bin size. The obtained data set was
normalized by the annulus area within which the particles were counted (thickness
corresponds to the bin size, 5 nm):
www.nature.com/scientificreports
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nd represents the number of gold-labelled particles counted inside the annulus area
(2pr2d) – (2pr2d-(d-5)) and d is a given distance from the analyzed particles.
Statistics. Statistical comparisons were carried out using the graph prism suite of
software. One-way analysis of variance analysis (ANOVA) was carried out with
Tukey’s post hoc correction. Significance was considered to be ,0.05.
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